We developed a novel and potentially clinically-applicable method to grow tolerogenic dendritic cells ex vivo. High IFN-? doses trigger remarkable tolerogenic properties in human monocyte-derived DCs (termed ?DCs), characterized by abundant expression of ILT4 and HLA-G and the ability of ?DCs to induce allogeneic IL-10-secreting CD4+ T cells. For this reason, the current method can allow clinical application of tolerogenic DCs in therapies of patients with immune dysfunctions, chronic autoimmune diseases and infections.
F.13 Development of new production methods and tools or processes
COBISS.SI-ID: 2999921The discovery of tumor-associated antigens, together with an improved insight in dendritic cell (DC) biology illustrating their key function in the immune system, have provided a rationale to initiate DC based cancer immunotherapy. DC vaccination is at an early stage, as methods for preparing tumor antigen presenting DC and improving their immunostimulatory function are continuously being optimized. Here, the developments in clinical DC generation, antigen loading methods and immunomonitoring approaches for DC-based vaccination therapy are presented.
F.18 Transfer of new know-how to direct users (seminars, fora, conferences)
COBISS.SI-ID: 2999409